At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
MAR001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of MAR001 in Patients With Metabolic Dysfunction
In Brief
A Phase 2 clinical trial evaluating MAR001 and Placebo for Hypertriglyceridemia. Completed, enrolled 55 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and tolerability of multiple doses of MAR001in adult volunteers with metabolic dysfunction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertriglyceridemia
CountriesAustralia
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
First PostedJun 2023
Enrollment StartJul 2023
Primary CompletionDec 2024
TodayJul 2026
First PostedJun 9, 2023
Enrollment StartJul 22, 2023
Primary CompletionDec 13, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.1 years ago
Interventions
MAR001drug
Subcutaneous injection
Placebodrug
Subcutaneous injection